# A universal material transfer agreement with a thirty-day default

Source: https://onco.cc/ideas/idea-fund-universal-mta-fast-lane/  
OnCo record `idea-fund-universal-mta-fast-lane` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Getting a cell line, mouse model or antibody from another lab can take six months of paperwork. Funders would require a standard agreement that goes through automatically unless someone objects within thirty days.

## Summary

Funders and journals require that materials generated with their support are shared under the Uniform Biological Material Transfer Agreement or an equivalent open template (for example the OpenMTA for tool reagents), with institutions committing to a thirty-day default-approve process for non-commercial requests and to deposit the most requested reagents in repositories (Addgene, ATCC, JAX, EurOPDX). Material access delays are a documented cause of failed replications and slow translation; the fix is procedural, not scientific, and costs almost nothing.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Funder-mandated standard MTAs reduce median time from request to receipt of research materials at participating institutions from months to under thirty days and increase the deposit rate of published reagents in public repositories above 80% within two years.
- Rationale: Addgene shows that repository deposit with standard terms makes sharing near-frictionless for plasmids; the UBMTA has existed since 1995 but is undermined by institutional insistence on bespoke terms. Funder mandates worked for data sharing and open access.
- Proposed test: Two funders adopt the mandate for one year; survey request-to-receipt times and repository deposit rates at grantee institutions before and after.
- Maturity: speculative
- Actor: policy

## Sources

- Addgene: https://www.addgene.org/
- OpenMTA: https://openmta.org/

## Connected records

- collections: [Cancer Models (PDCM Finder) & HCMI](https://onco.cc/collections/cancer-models/)
- ideas: [A regulator-endorsed standard contract for inter-company combination trials](https://onco.cc/ideas/idea-fund-standard-combination-agreement/), [Promote academics for trials completed, data shared and findings replicated](https://onco.cc/ideas/idea-fund-academic-promotion-reform/)
- technologies: [Patient-derived organoids](https://onco.cc/technologies/organoids/), [Patient-derived xenografts](https://onco.cc/technologies/pdx-models/)
- bottlenecks: [Preclinical results do not reproduce](https://onco.cc/bottlenecks/b-reproducibility/), [Secrecy and intellectual property block collaboration](https://onco.cc/bottlenecks/b-ip-collaboration/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-universal-mta-fast-lane.json